Industry news that matters to you.  Learn more

Health Discovery Corporation Announces Issuance of First Patent Covering Prostate Cancer Biomarkers

Reading time: 2 minutes

Health Discovery Corporation is pleased to announce that the United States Patent and Trademark Office has issued the first of what the Company expects to be several patents covering methods to screen for the presence of prostate cancer using genomic biomarkers that were identified by HDC researchers using the Company’s patented RFE-SVM algorithm.

The genomic biomarkers covered by the claims of HDC’s Patent No. 8,008,012, each performs well individually to distinguish prostate cancer from non-cancer (normal and BPH), however, the unique combination of the genomic biomarkers comprising this HDC prostate cancer test produced an overall test accuracy of 89%. By comparison, the PCA3 test for prostate cancer, developed by Gen-Probe Incorporated and commercially on sale in the United States and Europe, has been reported as having an overall test accuracy of around 81%, while overall test accuracy for PSA is only about 47%.
With the issuance of the new patent, HDC now holds exclusive rights to a total of 55 issued U.S. and foreign patents. HDC has a total of 88 patents pending and issued.

“HDC is very pleased to receive notice from the United States Patent and Trademark Office that the first of several HDC prostate biomarker patents has now been approved and issued“, stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “HDC remains firmly committed to successfully monetizing our valuable intellectual property through additional licensing, close collaboration, development and commercialization with our business partners and we will also continue to protect our patent portfolio through robust enforcement action when strategically appropriate”.

Source: Health Discovery Corporation